interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Rocuronium Bromide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Rocuronium Bromide, and who makes it?

Rocuronium Bromide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 14.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Rocuronium Bromide2 dosage-form groups in the Orange Book
18generic makers listed
  1. Rocuronium Bromide appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 18 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 14.7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Injectable, Injection

Four or more generic makers listed

Every brand product here is listed as discontinued. 18 generic makers with 35 generic products listed as marketed; the first generic approval is dated 26 November 2008.

199019952000200520102015202020252030018brand 1994Hospira Inc, first approval 26 November 2008Mylan Institutional Llc, first approval 26 November 2008Sandoz Inc, first approval 5 December 2008Fresenius Kabi Usa Llc, first approval 29 December 2008Sagent Pharmaceuticals Inc, first approval 28 July 2010Tamarang Sa, first approval 27 August 2012West Ward Pharmaceutical Corp, first approval 28 February 2017Eugia Pharma Specialities Ltd, first approval 12 April 2017Gland Pharma Ltd, first approval 4 April 2018Piramal Critical Care Inc, first approval 13 August 2019Prinston Pharmaceutical Inc, first approval 26 May 2022Caplin Steriles Ltd, first approval 2 March 2023Meitheal Pharmaceuticals Inc, first approval 8 May 2023Shandong New Time Pharmaceutical Co Ltd, first approval 12 July 2024Steriscience Pte Ltd, first approval 22 July 2024Mankind Pharma Ltd, first approval 29 May 2025Aspiro Pharma Ltd, first approval 4 March 2026Baxter Healthcare Corp, first approval 18 September 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Hospira Inc26 November 20082
Mylan Institutional Llc26 November 20082
Sandoz Inc5 December 20082
Fresenius Kabi Usa Llc29 December 20082
Sagent Pharmaceuticals Inc28 July 20102
Tamarang Sa27 August 20122
West Ward Pharmaceutical Corp28 February 20172
Eugia Pharma Specialities Ltd12 April 20172
Gland Pharma Ltd4 April 20182
Piramal Critical Care Inc13 August 20192
Prinston Pharmaceutical Inc26 May 20222
Caplin Steriles Ltd2 March 20232

6 more makers are listed in the data.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Rocuronium Bromide. No generic is listed as marketed.

2020202520302035204001brand 2025data datePatent 11998605 listed to expire 22 July 2039
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 22 July 2039Patent 11998605 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.